The nasal drug delivery technology market size has grown strongly in recent years. It will grow from $85.23 billion in 2025 to $92.28 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to growing prevalence of respiratory and neurological disorders, increased use of non-invasive drug delivery routes, expansion of nasal allergy treatments, availability of simple self-administration devices, rising acceptance of nasal therapeutics.
The nasal drug delivery technology market size is expected to see strong growth in the next few years. It will grow to $129.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing investments in CNS drug development, rising demand for rapid-onset therapies, expansion of nasal vaccine research, growing adoption of patient-friendly delivery systems, continuous innovation in nasal formulation technologies. Major trends in the forecast period include increasing adoption of nasal spray drug formulations, rising focus on brain-targeted drug delivery, growing development of novel nasal drug devices, expansion of vaccine and emergency therapeutic applications, enhanced emphasis on rapid drug absorption.
The rising prevalence of chronic diseases is projected to stimulate growth in the nasal drug delivery technology market. Chronic diseases are defined as health conditions that persist for a year or more and necessitate continuous medical care, potentially limiting daily activities. Nasal drug delivery technologies are utilized to manage chronic rhinosinusitis, enhancing bacterial biofilm management and mucociliary clearance through a therapeutic approach tailored for the intricate structure of the nasal cavity. For example, in April 2025, the Centers for Disease Control and Prevention (CDC) reported that in 2023, around 194 million adults in the United States, representing 76.4% of the adult population, were living with at least one chronic condition, while approximately 130 million adults, or 51.4%, were affected by two or more chronic conditions. As a result, the increasing prevalence of chronic diseases is fueling the expansion of the nasal drug delivery systems market.
Companies active in nasal drug delivery technologies are increasingly prioritizing collaborative innovation to develop advanced solutions such as nasal powder delivery devices, with a focus on improving accuracy, ease of use, and therapeutic performance, reflecting a broader strategic emphasis on product innovation. Nasal powder delivery devices are specifically engineered to administer powdered formulations through the nasal route, supporting local, systemic, and nose-to-brain drug delivery applications. For instance, in November 2023, Hovione LLC., a Portugal-based pharmaceutical company specializing in contract development and manufacturing of active pharmaceutical ingredients and drug product intermediates, partnered with Industrial Design Consultancy (IDC), a United Kingdom-based product design and development firm, to create a next-generation nasal powder delivery device platform. The collaboration aims to accelerate the development and commercialization of two new nasal powder devices, including one single-use and one multidose format, intended for local, systemic, and nose-to-brain therapies. These devices are designed to deliver precise and flexible nasal deposition, improve usability and reliability, and simplify drug development and manufacturing by maintaining compatibility with standard capsules and filling equipment. Hovione will offer these devices exclusively as part of its integrated nasal drug development and manufacturing solutions.
In October 2024, AptarGroup Inc., a United States-based global provider of drug delivery systems, completed the acquisition of the device-technology assets of SipNose LTD. Nasal Delivery Systems for an undisclosed consideration. This acquisition is intended to expand Aptar’s capabilities in intranasal and central nervous system drug delivery by incorporating SipNose’s proprietary platforms developed for local, systemic, and nose-to-brain administration. SipNose LTD. is an Israel-based company specializing in targeted intranasal drug delivery technologies, and its assets are expected to strengthen Aptar’s innovation pipeline and competitive positioning in advanced nasal drug delivery solutions.
Major companies operating in the nasal drug delivery technology market are AptarGroup Inc., Becton Dickinson and Company, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc., 3M Company, Cadila Healthcare Limited, Neurelis Inc., OptiNose Inc., Bausch Health Companies Inc., Naveh Pharma Ltd., Teva Pharmaceutical Industries Ltd., Consort Medical plc, Douglas Pharmaceuticals Ltd., ENT Technologies Pty Ltd, Merck & Co Inc, Sanofi SA, AstraZeneca plc, Boehringer Ingelheim International GmbH, Bayer AG, Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Roche Holding AG, Allergan plc.
North America was the largest region in the nasal drug delivery technology market in 2025. The regions covered in the nasal drug delivery technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nasal drug delivery technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the nasal drug delivery technology market by increasing costs of imported pharmaceutical-grade polymers, spray devices, metering systems, packaging materials, and precision manufacturing equipment. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported delivery components, while Asia-Pacific faces higher costs in device exports. These tariffs are increasing production expenses and impacting pricing strategies. However, they are also encouraging localized device manufacturing, regional supplier partnerships, and innovation in cost-efficient nasal delivery platforms.
The nasal drug delivery technology market research report is one of a series of new reports that provides nasal drug delivery technology market statistics, including nasal drug delivery technology industry global market size, regional shares, competitors with a nasal drug delivery technology market share, detailed nasal drug delivery technology market segments, market trends and opportunities, and any further data you may need to thrive in the nasal drug delivery technology industry. This nasal drug delivery technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Nasal drug delivery technology involves administering pharmaceuticals through the nasal cavity, aiming to rapidly achieve therapeutic drug levels in the bloodstream and potentially enable direct drug delivery to the brain via olfactory neurons. This method bypasses the blood-brain barrier (BBB) and undergoes minimal processing in the liver and intestines.
Key dosage forms for this technology include nasal spray, nasal drops, nasal gels, ointments, powders, and others. Nasal spray devices expel numerous tiny liquid drops to cleanse the nose or deliver medication to the body. They are available in pressurized and non-pressurized containers and are applied across diverse uses such as allergic and non-allergic rhinitis, nasal congestion, asthma, vaccination, and more. These products are accessible through various distribution channels such as hospital pharmacies, retail outlets, and online pharmacies, and are utilized by end-users including home care settings and hospitals.
The nasal drug delivery technology market consists of revenues earned by entities by providing services such as intranasal drug delivery services, brain-targeted therapy, and mucosal vaccination. The market value includes the value of related goods sold by the service provider or included within the service offering. The nasal drug delivery technology market also includes sales of catheter-delivered drugs, nebulizers, and pressurized metered-dose inhalers (PMDIs) equipment which are used in providing nasal drug delivery technology services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The nasal drug delivery technology market size is expected to see strong growth in the next few years. It will grow to $129.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing investments in CNS drug development, rising demand for rapid-onset therapies, expansion of nasal vaccine research, growing adoption of patient-friendly delivery systems, continuous innovation in nasal formulation technologies. Major trends in the forecast period include increasing adoption of nasal spray drug formulations, rising focus on brain-targeted drug delivery, growing development of novel nasal drug devices, expansion of vaccine and emergency therapeutic applications, enhanced emphasis on rapid drug absorption.
The rising prevalence of chronic diseases is projected to stimulate growth in the nasal drug delivery technology market. Chronic diseases are defined as health conditions that persist for a year or more and necessitate continuous medical care, potentially limiting daily activities. Nasal drug delivery technologies are utilized to manage chronic rhinosinusitis, enhancing bacterial biofilm management and mucociliary clearance through a therapeutic approach tailored for the intricate structure of the nasal cavity. For example, in April 2025, the Centers for Disease Control and Prevention (CDC) reported that in 2023, around 194 million adults in the United States, representing 76.4% of the adult population, were living with at least one chronic condition, while approximately 130 million adults, or 51.4%, were affected by two or more chronic conditions. As a result, the increasing prevalence of chronic diseases is fueling the expansion of the nasal drug delivery systems market.
Companies active in nasal drug delivery technologies are increasingly prioritizing collaborative innovation to develop advanced solutions such as nasal powder delivery devices, with a focus on improving accuracy, ease of use, and therapeutic performance, reflecting a broader strategic emphasis on product innovation. Nasal powder delivery devices are specifically engineered to administer powdered formulations through the nasal route, supporting local, systemic, and nose-to-brain drug delivery applications. For instance, in November 2023, Hovione LLC., a Portugal-based pharmaceutical company specializing in contract development and manufacturing of active pharmaceutical ingredients and drug product intermediates, partnered with Industrial Design Consultancy (IDC), a United Kingdom-based product design and development firm, to create a next-generation nasal powder delivery device platform. The collaboration aims to accelerate the development and commercialization of two new nasal powder devices, including one single-use and one multidose format, intended for local, systemic, and nose-to-brain therapies. These devices are designed to deliver precise and flexible nasal deposition, improve usability and reliability, and simplify drug development and manufacturing by maintaining compatibility with standard capsules and filling equipment. Hovione will offer these devices exclusively as part of its integrated nasal drug development and manufacturing solutions.
In October 2024, AptarGroup Inc., a United States-based global provider of drug delivery systems, completed the acquisition of the device-technology assets of SipNose LTD. Nasal Delivery Systems for an undisclosed consideration. This acquisition is intended to expand Aptar’s capabilities in intranasal and central nervous system drug delivery by incorporating SipNose’s proprietary platforms developed for local, systemic, and nose-to-brain administration. SipNose LTD. is an Israel-based company specializing in targeted intranasal drug delivery technologies, and its assets are expected to strengthen Aptar’s innovation pipeline and competitive positioning in advanced nasal drug delivery solutions.
Major companies operating in the nasal drug delivery technology market are AptarGroup Inc., Becton Dickinson and Company, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc., 3M Company, Cadila Healthcare Limited, Neurelis Inc., OptiNose Inc., Bausch Health Companies Inc., Naveh Pharma Ltd., Teva Pharmaceutical Industries Ltd., Consort Medical plc, Douglas Pharmaceuticals Ltd., ENT Technologies Pty Ltd, Merck & Co Inc, Sanofi SA, AstraZeneca plc, Boehringer Ingelheim International GmbH, Bayer AG, Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Roche Holding AG, Allergan plc.
North America was the largest region in the nasal drug delivery technology market in 2025. The regions covered in the nasal drug delivery technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nasal drug delivery technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the nasal drug delivery technology market by increasing costs of imported pharmaceutical-grade polymers, spray devices, metering systems, packaging materials, and precision manufacturing equipment. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported delivery components, while Asia-Pacific faces higher costs in device exports. These tariffs are increasing production expenses and impacting pricing strategies. However, they are also encouraging localized device manufacturing, regional supplier partnerships, and innovation in cost-efficient nasal delivery platforms.
The nasal drug delivery technology market research report is one of a series of new reports that provides nasal drug delivery technology market statistics, including nasal drug delivery technology industry global market size, regional shares, competitors with a nasal drug delivery technology market share, detailed nasal drug delivery technology market segments, market trends and opportunities, and any further data you may need to thrive in the nasal drug delivery technology industry. This nasal drug delivery technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Nasal drug delivery technology involves administering pharmaceuticals through the nasal cavity, aiming to rapidly achieve therapeutic drug levels in the bloodstream and potentially enable direct drug delivery to the brain via olfactory neurons. This method bypasses the blood-brain barrier (BBB) and undergoes minimal processing in the liver and intestines.
Key dosage forms for this technology include nasal spray, nasal drops, nasal gels, ointments, powders, and others. Nasal spray devices expel numerous tiny liquid drops to cleanse the nose or deliver medication to the body. They are available in pressurized and non-pressurized containers and are applied across diverse uses such as allergic and non-allergic rhinitis, nasal congestion, asthma, vaccination, and more. These products are accessible through various distribution channels such as hospital pharmacies, retail outlets, and online pharmacies, and are utilized by end-users including home care settings and hospitals.
The nasal drug delivery technology market consists of revenues earned by entities by providing services such as intranasal drug delivery services, brain-targeted therapy, and mucosal vaccination. The market value includes the value of related goods sold by the service provider or included within the service offering. The nasal drug delivery technology market also includes sales of catheter-delivered drugs, nebulizers, and pressurized metered-dose inhalers (PMDIs) equipment which are used in providing nasal drug delivery technology services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Nasal Drug Delivery Technology Market Characteristics
3. Nasal Drug Delivery Technology Market Supply Chain Analysis
4. Global Nasal Drug Delivery Technology Market Trends and Strategies
5. Nasal Drug Delivery Technology Market Analysis of End Use Industries
7. Global Nasal Drug Delivery Technology Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Nasal Drug Delivery Technology Total Addressable Market (TAM) Analysis for the Market
9. Nasal Drug Delivery Technology Market Segmentation
10. Nasal Drug Delivery Technology Market Regional and Country Analysis
11. Asia-Pacific Nasal Drug Delivery Technology Market
12. China Nasal Drug Delivery Technology Market
13. India Nasal Drug Delivery Technology Market
14. Japan Nasal Drug Delivery Technology Market
15. Australia Nasal Drug Delivery Technology Market
16. Indonesia Nasal Drug Delivery Technology Market
17. South Korea Nasal Drug Delivery Technology Market
18. Taiwan Nasal Drug Delivery Technology Market
19. South East Asia Nasal Drug Delivery Technology Market
20. Western Europe Nasal Drug Delivery Technology Market
21. UK Nasal Drug Delivery Technology Market
22. Germany Nasal Drug Delivery Technology Market
23. France Nasal Drug Delivery Technology Market
24. Italy Nasal Drug Delivery Technology Market
25. Spain Nasal Drug Delivery Technology Market
26. Eastern Europe Nasal Drug Delivery Technology Market
27. Russia Nasal Drug Delivery Technology Market
28. North America Nasal Drug Delivery Technology Market
29. USA Nasal Drug Delivery Technology Market
30. Canada Nasal Drug Delivery Technology Market
31. South America Nasal Drug Delivery Technology Market
32. Brazil Nasal Drug Delivery Technology Market
33. Middle East Nasal Drug Delivery Technology Market
34. Africa Nasal Drug Delivery Technology Market
36. Nasal Drug Delivery Technology Market Competitive Landscape and Company Profiles
37. Nasal Drug Delivery Technology Market Other Major and Innovative Companies
40. Nasal Drug Delivery Technology Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Nasal Drug Delivery Technology Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses nasal drug delivery technology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for nasal drug delivery technology? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nasal drug delivery technology market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Dosage Form: Nasal Spray; Nasal Drops; Nasal Gels And Ointments; Nasal Powders; Other Dosage Forms2) By Container Type: Pressurized Containers; Non-Pressurized Containers
3) By Therapeutic Application: Allergic And Non-Allergic Rhinitis; Nasal Congestion; Vaccination; Other Therapeutic Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Home Care Settings; Hospitals
Subsegments:
1) By Nasal Spray: Metered-Dose Spray; Non-Metered-Dose Spray2) By Nasal Drops: Liquid Nasal Drops; Gel-Based Nasal Drops
3) By Nasal Gels and Ointments: Hydrogel Formulations; Oil-Based Ointments
4) By Nasal Powders: Dry Powder Inhalers (DPI); Spray-Dried Powders
5) By Other Dosage Forms: Nasal Patches; Nasal Inserts
Companies Mentioned: AptarGroup Inc.; Becton Dickinson and Company; GlaxoSmithKline plc; Johnson & Johnson Private Limited; Novartis AG; Pfizer Inc.; 3M Company; Cadila Healthcare Limited; Neurelis Inc.; OptiNose Inc.; Bausch Health Companies Inc.; Naveh Pharma Ltd.; Teva Pharmaceutical Industries Ltd.; Consort Medical plc; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty Ltd; Merck & Co Inc; Sanofi SA; AstraZeneca plc; Boehringer Ingelheim International GmbH; Bayer AG; Abbott Laboratories; Eli Lilly and Company; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Roche Holding AG; Allergan plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Nasal Drug Delivery Technology market report include:- AptarGroup Inc.
- Becton Dickinson and Company
- GlaxoSmithKline plc
- Johnson & Johnson Private Limited
- Novartis AG
- Pfizer Inc.
- 3M Company
- Cadila Healthcare Limited
- Neurelis Inc.
- OptiNose Inc.
- Bausch Health Companies Inc.
- Naveh Pharma Ltd.
- Teva Pharmaceutical Industries Ltd.
- Consort Medical plc
- Douglas Pharmaceuticals Ltd.
- ENT Technologies Pty Ltd
- Merck & Co Inc
- Sanofi SA
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Bayer AG
- Abbott Laboratories
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Roche Holding AG
- Allergan plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 92.28 Billion |
| Forecasted Market Value ( USD | $ 129.23 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
